home / stock / goss / goss articles
Oppenheimer initiated coverage on Gossamer Bio Inc (NASDAQ:GOSS), a clinical-stage biopharmaceutical company, with an Outperform rating and a price...
The Dow Jones index closed higher by over 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern aro...
Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0...
Shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) fell sharply during Monday’s session after the company and POINT Biopharma announced topline...
John Quisel, Director at Gossamer Bio (NASDAQ:GOSS), reported a large acquisition of company stock options on November 29, according to a new SEC f...
The Dow Jones closed higher by around 490 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around...
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Gossamer Bio, Inc. (NASDAQ:GOSS) on behalf of...
STAMFORD, Conn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Gossamer Bio, Inc. (NASDAQ:GOSS) ("Gossamer" or the "Comp...
News, Short Squeeze, Breakout and More Instantly...
2024-06-24 17:15:03 ET Oppenheimer analyst issues OUTPERFORM recommendation for GOSS on June 24, 2024 04:04PM ET. The previous analyst recommendation was Buy. GOSS was trading at $0.8261 at issue of the analyst recommendation. The overall analyst consensus : BUY. Cur...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), will present up...
- Transformative Development and Co-Commercialization Collaboration with Chiesi - - Ongoing PROSERA Phase 3 Study in PAH Expected to Readout in Q4 2025 - - Registrational Phase 3 in PH-ILD Expected to Commence in Mid-2025 - - TORREY Phase 2 PAH Results Published in Lancet ...